Evaluating the Utility of a ‘N-of-1' Precision Cancer Medicine Strategy: The Case for ‘Time-to-Subsequent-Disease Progression'

Publisher： Karger

E-ISSN： 1423-0232|91|6|299-301

ISSN： 0030-2414

Source： Oncology, Vol.91, Iss.6, 2016-10, pp. : 299-301

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?

By Lillie Elizabeth O   Patay Bradley   Diamant Joel   Issell Brian   Topol Eric J   Schork Nicholas J  

Personalized Medicine, Vol. 8, Iss. 2, 2011-03 ,pp. : 161-173

Future Medicine

Access to resources Recommend Favorite

Utility of a Precision Medicine Test in Elderly Adults with Symptoms Suggestive of Coronary Artery Disease

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 66, Iss. 2, 2018-02 ,pp. : 309-315

John Wiley & Sons Inc

Access to resources Recommend Favorite

Minimizing inequality in access to precision medicine in breast cancer by real‐time population‐based molecular analysis in the SCAN‐B initiative

By  

BRITISH JOURNAL OF SURGERY, Vol. 105, Iss. 2, 2018-01 ,pp. : e158-e168

John Wiley & Sons Inc

Access to resources Recommend Favorite

Applying precision medicine to the active surveillance of prostate cancer

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3403-3411

John Wiley & Sons Inc

Access to resources Recommend Favorite

Molecular Pathology: A Requirement for Precision Medicine in Cancer

By  

Oncology Research and Treatment, Vol. 39, Iss. 12, 2016-11 ,pp. : 804-810

Karger

Access to resources Recommend Favorite